Ruxience is paid 92.0% below Rituxan

3 biosimilars bill against Rituxan (J9312). On average they are paid ↓ 70.9% relative to the reference product per 10 MG in 4Q26.

Rituxan (reference)
Ruxience
Riabni
Truxima

Payment limit per 10 MG, last 8 quarters. Reference product as the thick navy line, biosimilars in teal and other colors.

All products

Product	Code	CMS description	Per 10 MG	vs. reference	CMS 8% add-on note
Rituxan	J9312	Inj., rituximab, 10 mg	$72.094	Reference	–
Ruxience	Q5119	Inj ruxience, 10 mg	$5.792	↓ 92.0%	No
Riabni	Q5123	Inj. riabni, 10 mg	$21.083	↓ 70.8%	Yes
Truxima	Q5115	Inj truxima 10 mg	$35.988	↓ 50.1%	Yes

Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.